Case report of a rare urinary bladder tumor variant (carcinosarcoma)

Althubiany, Hatem Hamed; Hasan, Rami; Alzahrani, Saeed Abdullah; Bahdilh, Salem

doi:10.4103/ua.ua_76_19

Cited by 4 publications

(15 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most of the available literature is case reports and literature reviews with small numbers of cases. [6][7][8][9] To the best of our knowledge, no prospective study or clinical trial on BCS has been published, and only two retrospective studies published in English included a large sample size. [12][13][14] One identified 221 BCS patients in the SEER 17 registries diagnosed between 1973 and 2004; the other enrolled 3007 patients with genitourinary sarcomas diagnosed from 1973 to 2015 from the SEER 18 registries.…”

Section: Subgroup Analysismentioning

confidence: 99%

“…13 These results are similar to our findings. [6][7][8][9][14][15][16][17][18][19] Further, Nazemi et al showed that most patients (95.9%) underwent cancer-directed surgery, whereas only a small proportion of patients received radiation (16.7%). 13 We observed similar characteristics in our cohort.…”

Section: Subgroup Analysismentioning

confidence: 99%

“…5 Published case reports indicate that BCS has high rates of recurrence and metastasis, and patients present with poor differentiation and advanced stage, leading to poor prognosis. [6][7][8][9] In addition, BCS is thought to have outcomes similar to those of bladder TCC. 10 The sample sizes of previous studies are too small to provide conclusive results.…”

Section: Introductionmentioning

confidence: 99%

“…10 The sample sizes of previous studies are too small to provide conclusive results. [6][7][8][9][10] Therefore, a large population-based study with the intent to compare BCS and conventional bladder cancer (TCC, SCC or AC) is warranted. In this study, we reviewed the Surveillance, Epidemiology, and End Results (SEER) database to compare clinicopathological characteristics and outcomes of patients with BCS and conventional bladder cancer.…”

Section: Introductionmentioning

confidence: 99%

“…In addition, BCS is thought to have outcomes similar to those of bladder TCC 10 . The sample sizes of previous studies are too small to provide conclusive results 6–10 . Therefore, a large population‐based study with the intent to compare BCS and conventional bladder cancer (TCC, SCC or AC) is warranted.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Carcinosarcoma is an aggressive subtype of bladder cancer: A population‐based study

2022

View full text Add to dashboard Cite

Background Case reports of bladder carcinosarcoma (BCS) indicate high rates of recurrence and metastasis and poor prognosis. However, the differences in clinicopathologic characteristics and prognosis between BCS and conventional bladder cancer histologies (transitional cell carcinoma [TCC], squamous cell carcinoma [SCC] and adenocarcinoma [AC]) have not been fully clarified in a large study. Therefore, we conducted a large population‐based study to further investigate these differences. Patients and methods Information on patients with BCS and conventional bladder cancer (TCC, SCC or AC) was extracted from the Surveillance, Epidemiology, and End Results database. Categorical variables were compared using Pearson's chi‐squared test or Fisher's exact test. Survival analysis was carried out using the Kaplan–Meier method, and differences in survival were assessed using the log‐rank test. Propensity score matching analysis was conducted to calibrate the differences between the baseline characteristics, after which Cox regression analysis was applied to calculate the hazard ratios and 95% confidence intervals of BCS compared to other subtypes. Subgroup analysis and related interaction were tested to evaluate the consistency and heterogeneity of results. Results We enrolled 152 patients with BCS and 180,196 patients with TCC, SCC or AC. Our results showed that BCS was associated with poor differentiation, advanced stage and an unfavourable overall survival and cancer‐specific survival. BCS had a worse prognosis than TCC and AC, but no statistically significant difference in survival was noted between BCS and SCC. Conclusions BCS is a more aggressive bladder cancer than TCC and AC but is comparable to SCC. These findings broaden our understanding of BCS and may be helpful in clinical practice.

show abstract

Section: Subgroup Analysismentioning

confidence: 99%

Section: Subgroup Analysismentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Carcinosarcoma is an aggressive subtype of bladder cancer: A population‐based study

2022

View full text Add to dashboard Cite

show abstract

Bladder carcinosarcoma treated by cystectomy and adjuvant chemotherapy with good outcomes: a case report

Kouhen,

Dahbi,

Afif

et al. 2023

J Med Case Reports

View full text Add to dashboard Cite

Background Primary carcinosarcoma of the bladder is a rare and highly aggressive tumor, representing less than 1% of all bladder neoplasms. There is no specific treatment guideline has for carcinosarcoma of the bladder, and majority of published patients was treated exclusively by surgery. Case presentation We report a case of 65-year-old Moroccan man, presented with macroscopic hematuria, pollakiuria and painful urination. Histological analysis showed a biphasic epithelial and mesenchymal proliferation, with invasion of lamina propria and muscularis, compatible with diagnosis of bladder carcinosarcoma. The patient was treated with cystectomy and adjuvant chemotherapy based on gemcitabin-cisplatin, 18 months after treatment, patient still free of recurrence. Conclusion Carcinosarcoma of the urinary bladder is a rare and aggressive tumor regardless treatment. A multidisciplinary management based on radical cystectomy and combined adjuvant treatments can improve prognosis. In this work, we suggest to propose adjuvant chemotherapy whenever possible.

show abstract

Clinical efficacy analysis of partial cystectomy and radical cystectomy in the treatment of muscle-invasive sarcomatoid carcinoma of the urinary bladder

Xiao,

Chen,

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveThis study compares the clinical efficacy of partial cystectomy (PC) versus radical cystectomy (RC) in the treatment of muscle-invasive bladder urothelial carcinoma (SCUB) through a retrospective analysis.MethodsWe retrospectively analyzed the clinical data of 20 patients diagnosed with muscle-invasive SCUB from July 2015 to August 2023 at Ganzhou People’s Hospital. All patients underwent surgical treatment followed by chemotherapy, with 9 receiving PC and 11 undergoing RC. We compared the average survival time of deceased patients for both treatments and conducted survival and multivariate analyses using the Kaplan-Meier method and Cox proportional hazards model, respectively.ResultsAll 20 patients were postoperatively diagnosed with muscle-invasive SCUB and were followed up for 4 to 60 months. The average survival time for patients undergoing PC was 11.5 months, with survival rates at 1 year, 2 years, and 5 years of 55.56%, 22.22%, and 11.11%, respectively. In contrast, patients receiving RC had an extended average survival time of 22.5 months, and their 1-year, 2-year, and 5-year survival rates increased to 63.64%, 36.36%, and 18.18%, respectively. Survival analysis revealed statistically significant differences in prognosis between PC and RC for the treatment of muscle-invasive SCUB (P<0.05).ConclusionSCUB is a rare malignant tumor with unique biological characteristics often associated with poor prognosis. Upon diagnosis, RC should be considered as an early treatment approach when the patient’s overall condition permits.

show abstract

Case report of a rare urinary bladder tumor variant (carcinosarcoma)

Cited by 4 publications

References 3 publications

Carcinosarcoma is an aggressive subtype of bladder cancer: A population‐based study

Carcinosarcoma is an aggressive subtype of bladder cancer: A population‐based study

Bladder carcinosarcoma treated by cystectomy and adjuvant chemotherapy with good outcomes: a case report

Clinical efficacy analysis of partial cystectomy and radical cystectomy in the treatment of muscle-invasive sarcomatoid carcinoma of the urinary bladder

Contact Info

Product

Resources

About